Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells

Emami, Ali; Babaei, Esmaeil; Nagishbandi, Alaadin; Azeez, Hewa Jalal; Feizi, Mohammad Ali Hosseinpour; Golizadeh, Ashraf

doi:10.1007/s11033-021-06713-2

Cited by 6 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemini-Cur is one of the latest nano-formulations of curcumin with a significant anticancer effect that has recently been developed by our group [ 15 ]. We have already reported that Gemini-Cur inhibits the proliferation of different cancer cells through the induction of apoptosis [ 13 , 14 , 15 , 16 ]. Due to the limited information on the global effect of curcumin on transcriptome profiling, we employed RNA sequencing to uncover the differentially expressed genes and cellular pathways that are affected by Gemini-Cur in colorectal cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…We have previously reported the IC50 values for Gemini-Cur on HCT-116 cells. Furthermore, we demonstrated that Gemini-Cur modulates the cell cycle and induces apoptosis in HCT-116 cells compared to controls [ 14 ]. To further confirm cellular toxicity on the cells treated with Gemini-Cur, we used ethidium bromide/acridine orange (EB/AO) staining.…”

Section: Methodsmentioning

confidence: 99%

“…Despite these tempting advantages of curcumin, the poor bioavailability limits its exploitation as a therapeutic compound [ 12 ]. Our team has recently formulated and characterized a nano-based encapsulated curcumin, gemini curcumin (Gemini-Cur), with significant anticancer effects on ovarian, gastric, breast and colorectal cancer [ 13 , 14 , 15 , 16 ]. Briefly, gemini surfactant nanoparticles belong to a surfactant family with two identical structures that are linked by a rigid or flexible spacer that could harbor and deliver drugs and genes into the cells and tissues.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transcriptome Profiling of HCT-116 Colorectal Cancer Cells with RNA Sequencing Reveals Novel Targets for Polyphenol Nano Curcumin

Azeez

Neri²,

Feizi³

et al. 2022

Molecules

Self Cite

View full text Add to dashboard Cite

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. The gemini nanoparticle formulation of polyphenolic curcumin significantly inhibits the viability of cancer cells. However, the molecular mechanisms and pathways underlying its toxicity in colon cancer are unclear. Here, we aimed to uncover the possible novel targets of gemini curcumin (Gemini-Cur) on colorectal cancer and related cellular pathways. After confirming the cytotoxic effect of Gemini-Cur by MTT and apoptotic assays, RNA sequencing was employed to identify differentially expressed genes (DEGs) in HCT-116 cells. On a total of 3892 DEGs (padj < 0.01), 442 genes showed a log2 FC >|2| (including 244 upregulated and 198 downregulated). Gene ontology (GO) enrichment analysis was performed. Protein–protein interaction (PPI) and gene-pathway networks were constructed by using STRING and Cytoscape. The pathway analysis showed that Gemini-Cur predominantly modulates pathways related to the cell cycle. The gene network analysis revealed five central genes, namely GADD45G, ATF3, BUB1B, CCNA2 and CDK1. Real-time PCR and Western blotting analysis confirmed the significant modulation of these genes in Gemini-Cur-treated compared to non-treated cells. In conclusion, RNA sequencing revealed novel potential targets of curcumin on cancer cells. Further studies are required to elucidate the molecular mechanism of action of Gemini-Cur regarding the modulation of the expression of hub genes.

show abstract